Msefsl

CLOSE X

Risk Disclosures on Derivatives

>9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
>On an average, loss makers registered net trading loss close to ₹ 50,000.
>Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
>Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.

JENBURKT PHARMACEUTICALS LTD.

NSE : NABSE : 524731ISIN CODE : INE354A01013Industry : Pharmaceuticals & DrugsHouse : Private

BSE1181.0017.8 (+1.53 %)

PREV CLOSE ( ) 1163.20

OPEN PRICE ( ) 1165.05

BID PRICE (QTY) 0.00 (0)

OFFER PRICE (QTY) 0.00 (0)

VOLUME 1841

TODAY'S LOW / HIGH ( )1165.00 1181.00

52 WK LOW / HIGH ( ) 9441410

NSE

This Company is not listed in NSE

BSE NSE

1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 1985

Management Info

Ashish U Bhuta - Chairman Ashish U Bhuta - Managing Director

Registered Office

Address Nirmala Apartments,93 Jayprakash Road,Andheri (West),
Mumbai,
Maharashtra-400058

Phone 022-67603603

Email investor@jenburkt.com / info@jenburkt.com

Website www.jenburkt.com

Registrars Details

Bigshare Services Pvt Ltd

Office No S6-2, 6th Floor, Pinnacle Business Park,Next to Ahura Centre, Mahakali Caves Road,Andheri (E),Mumbai

Listing : BSE

NEWS

05May Appointment of Director
Inter alia, approved:- 1. A dividend of 220.70/- (207%) per equity shar..

28Apr Dividend Announcement
Final Dividend & Audited Results & A.G.M. & Quarterly Results

14Apr Jenburkt Pharmaceuticals informs about
Pursuant to SEBI Circular SEBI/HO/DDHS/CIR/2021/613 dated 10th August, 2..

28Oct Jenburkt Pharmaceuticals informs about
Jenburkt Pharmaceuticals has informed that it enclosed Standalone Unaudi..

23Jun Jenburkt Pharmaceuticals informs about
With reference to letter no. JPL/CS/2206/2024 dated 20th June, 2025, Jen..

Financials

Rs. in Millions

	QTR Mar 26	ANNUAL 26
Net Profit	108.5	347.36
Gross Profit	137.09	465.19
Operating Profit	185.98	540.4
Net Sales	446.32	1687.41

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Abbott India (BSE) 26544.35 (1.52%)	M.Cap ( in Cr)56225.65
Kwality Pharma (BSE) 2500.00 (7.01%)	M.Cap ( in Cr)2575.48
Unichem Lab (BSE) 453.65 (20.00%)	M.Cap ( in Cr)3085.53
Ajanta Pharma (BSE) 3075.00 (2.09%)	M.Cap ( in Cr)38405.21
Caplin Point Lab (BSE) 2311.25 (2.38%)	M.Cap ( in Cr)17526.02

Shareholding Pattern

	NON-INSTITUTION	53.25%
	PROMOTERS	46.64%
	MUTUAL FUNDS/UTI	0%
	FI/BANKS/INSURANCE	0%
	GOVERNMENT	0%
	FII	0%

Mf Holdings

Scheme Name	Hold(%)
No Data Found

Risk Disclosures on Derivatives

Smart Quotes

JENBURKT PHARMACEUTICALS LTD.